| 姜培娣,李 宁,岳 建,王 雪,牛海涛.重组人血管内皮抑制素联合顺铂化疗治疗老年晚期非小细胞肺癌的临床疗效[J].,2017,17(13):2444-2449 |
| 重组人血管内皮抑制素联合顺铂化疗治疗老年晚期非小细胞肺癌的临床疗效 |
| Clinical Study on Recombinant Human Endostatin Combined with Cisplatin in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer |
| 投稿时间：2016-12-21 修订日期：2017-01-13 |
| DOI：10.13241/j.cnki.pmb.2017.13.011 |
| 中文关键词: 晚期非小细胞肺癌 重组人血管内皮抑制素 疗效 生存分析 |
| 英文关键词: Advanced non small cell lung cancer Recombinant human endostatin Therapeutic effects Survival analysis |
| 基金项目:北京市科学技术委员会重大项目（VERSION1.0_20160205） |
|
| 摘要点击次数: 625 |
| 全文下载次数: 218 |
| 中文摘要: |
| 摘要 目的：分析重组人血管内皮抑制素联合顺铂化疗方案治疗老年晚期非小细胞肺癌（NSCLC）的疗效和安全性。方法：选取82例老年晚期NSCLC患者作为研究对象，应用随机数字表将患者分为观察组和对照组，每组各41例。对照组患者给予含顺铂的两药化疗方案进行治疗，观察组患者在对照组疗法的基础上加用重组人血管内皮抑制素治疗。对两组患者的临床疗效、临床有效率（CRR）、临床受益率（CBR）进行评价。对两组患者治疗前后的Karnofsky评分、血清癌胚抗原（CEA）水平变化进行观察和比较。对两组患者进行随访，对患者的总生存期（OS）和疾病进展时间（TTP）进行观察和比较。对两组患者治疗期间不良反应发生率进行观察和比较。结果：观察组患者CRR和CBR均显著高于对照组，差异均有统计学意义（P<0.05）。两组患者治疗前、后Karnofsky评分的上升幅度和血清CEA水平的下降幅度的差异无统计学意义（P>0.05）。观察组患者和对照组患者的OS中位数估计值分别为16.720月和14.590月，TTP中位数估计值分别为6.260月和4.770月，两组患者OS和TTP中位数估计值的差异均有统计学意义（P<0.05）。两组患者不良反应发生率差异无统计学意义（P>0.05）。结论：在老年晚期NSCLC患者的治疗中，在含顺铂治疗方案基础上加用重组人血管内皮抑制素进行治疗，能够提高患者的临床受益和治疗有效率，延长患者的生存期，改善患者的预后，且未增加不良反应的发生率。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the efficacy and safety of recombinant human endostatin combined with cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). Methods: 82 elderly patients with advanced NSCLC were selected and randomly divided into the observation group and the control group, with 41 cases in each group. The patients in the control group were treated with chemotherapy, while the patients in the observation group were treated with combined recombinant human endostatin on the basis of the control group. Then the clinical therapeutic effects, the clinical remission rate (CRR) and the clinical benefit rate (CBR) in the two groups were observed and compared. The changes of Karnofsky scores, serum carcinoembryonic antigen (CEA) levels before and after the treatment of the two groups were observed and compared. The patients in the two groups were followed up, and the overall survival (OS) and the time to progression (TTP) of the patients in the two groups were observed and compared. The incidences of the adverse events during the treatment were observed and compared. Results: CRR and CBR of the patients in the observation group were significantly higher than those in the control group, and the differences between the two groups were statistically significant (P<0.05). There were no significant differences in increases of Karnofsky scores and decreases of serum CEA levels between the patients in the two groups (P>0.05). The estimated median of OS in observation group and the control group were 16.720 and 14.590 months. The estimated median of TTP was 6.260 and 4.770 months. There were statistically significant differences in estimated median of OS and TTP between the patients in the two groups (P<0.05). There were no statistically significant differences in incidences of adverse events between the patients in the two groups (P>0.05). Conclusion: In the treatment of elderly patients with advanced NSCLC, the application of recombinant human endostatin on the basis of chemotherapy including cisplatin can improve the treatment efficiency and benefit of the patients, prolong the survival time and improve the prognosis of the patients, and no increases of the incidences of adverse reactions are observed. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
